Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Pliant Therapeutics, Inc. - Common Stock (NQ:PLRX)

1.060 +0.010 (+0.95%)

Delayed Quote Updated: 9:53 AM EDT, Oct 2, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	22,988
Open	1.060
Bid (Size)	1.050 (4,100)
Ask (Size)	1.060 (2,900)
Prev. Close	1.050
Today's Range	1.051 - 1.065
52wk Range	1.020 - 1.950
Shares Outstanding	35,937,937
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Pliant Therapeutics Appoints David Raben, M.D., as Chief Medical Officer

September 30, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

August 18, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-15.2%	-15.2%
1 Month	-4.5%	-4.5%
3 Month	-9.4%	-9.4%
6 Month	-21.5%	-21.5%
1 Year	-26.9%	-26.9%

More News

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

August 11, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D., M.S.C.E. to Board of Directors

July 13, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 21, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 11, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 06, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

April 30, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

April 18, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

United Therapeutics Surges 14% on Groundbreaking Tyvaso Phase 3 Results for IPF

March 31, 2026

Via MarketMinute

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

March 18, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

March 11, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference

February 23, 2026

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Keep an eye on the top gainers and losers in Thursday's session. ↗

December 04, 2025

Via Chartmill

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

December 04, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

December 01, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 06, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

August 07, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

June 27, 2025

Via Benzinga

Get insights into the top gainers and losers of Friday's after-hours session. ↗

June 27, 2025

Via Chartmill

Pliant Therapeutics Provides Update on BEACON-IPF

June 27, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

May 21, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 08, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 05, 2025

Via Benzinga

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

May 01, 2025

From Pliant Therapeutics, Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Pliant Therapeutics, Inc. - Common Stock publicly traded?

Yes, Pliant Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Pliant Therapeutics, Inc. - Common Stock trade on?

Pliant Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Pliant Therapeutics, Inc. - Common Stock?

The ticker symbol for Pliant Therapeutics, Inc. - Common Stock is PLRX on the Nasdaq Stock Market

What is the current price of Pliant Therapeutics, Inc. - Common Stock?

The current price of Pliant Therapeutics, Inc. - Common Stock is 1.060

When was Pliant Therapeutics, Inc. - Common Stock last traded?

The last trade of Pliant Therapeutics, Inc. - Common Stock was at 10/02/26 09:53 AM ET

What is the market capitalization of Pliant Therapeutics, Inc. - Common Stock?

The market capitalization of Pliant Therapeutics, Inc. - Common Stock is 38.09M

How many shares of Pliant Therapeutics, Inc. - Common Stock are outstanding?

Pliant Therapeutics, Inc. - Common Stock has 38M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.